TrialDiabetes, obesity & metabolism2018

Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial.

Chantal Mathieu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.